Lisuride in Parkinson's disease. 4-Year follow-up

P. Giovannini, G. Scigliano, I. Piccolo, P. Soliveri, I. Scuhy, T. Caraceni

Research output: Contribution to journalArticlepeer-review


Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.

Original languageEnglish
Pages (from-to)201-211
Number of pages11
JournalClinical Neuropharmacology
Issue number3
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Lisuride in Parkinson's disease. 4-Year follow-up'. Together they form a unique fingerprint.

Cite this